MCM
BBIO icon

MAI Capital Management’s BridgeBio Pharma BBIO Stock Holding History

MAI Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28
Closed -$2.08K – 2335
2026
Q1 		$2.08K Buy
28
+23
+460% +$1.67K ﹤0.01% 3909
2025
Q4 		$383 Buy
+5
New +$328 ﹤0.01% 3906

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

MAI Capital Management's BBIO Position: Q2 2026 in Review

MAI Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 28 shares — an estimated $2.08K sold.

MAI Capital Management first reported a position in BBIO in Q4 2025 and held it in 2 quarters. The position peaked at $2.08K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • MAI Capital Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 28 BridgeBio Pharma shares in Q2 2026, an estimated $2.08K.
  • MAI Capital Management first reported a position in BridgeBio Pharma in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's BridgeBio Pharma position peaked at $2.08K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.